



ASX release

7 October 2014

SphygmoCor selected for US publicly-funded study

AtCor Medical (ASX:ACG), the developer and marketer of the SphygmoCor® system which noninvasively measures central aortic blood pressures and arterial stiffness, announced today that it has secured an order to supply SphygmoCor systems for a publicly-funded 14-centre cholesterol lowering study in obesity in the United States.

Duncan Ross, AtCor Medical CEO said, "We are delighted that SphygmoCor technology has been selected to provide measures of central blood pressure and arterial stiffness in a trial with significance to public health. SphygmoCor continues to be chosen as the preferred device in trials such as these due to the system's gold standard status, supporting clinical data and excellent customer support.

According to the American Heart Association, over 115 million US adults and children are obese which puts them at higher risk for health problems such as heart disease, stroke, high blood pressure, diabetes and more. The United States spends over US\$300 billion per year in direct and indirect costs for cardiovascular disease and stroke, with heart conditions being the leading diagnoses for direct healthcare expenditure. SphygmoCor will play an important role contributing to authoritative trial results."

About AtCor Medical

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central aortic blood pressure non-invasively. The company's SphygmoCor® system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 3,600 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 800 peer-reviewed studies published in leading medical journals along with thousands of citations. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com.

*For further information, please contact
(AtCor):*

Duncan Ross – AtCor Medical CEO
+1 (630) 228 8873

Peter Manley – AtCor Medical CFO
+61 (2) 8815 8811

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or
a.rambukwella@fcr.com.au